Affordable Access

deepdyve-link
Publisher Website

Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma.

Authors
  • Oliver, Jamie R1
  • Lieberman, Seth M2
  • Tam, Moses M3
  • Liu, Cheng Z4
  • Li, Zujun5
  • Hu, Kenneth S3
  • Morris, Luc G T6
  • Givi, Babak2
  • 1 New York University School of Medicine, New York, New York.
  • 2 Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, New York.
  • 3 Department of Radiation Oncology, NYU Langone Health, New York, New York.
  • 4 Department of Pathology, NYU Langone Health, New York, New York.
  • 5 Department of Medical Oncology, NYU Langone Health, New York, New York.
  • 6 Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Apr 01, 2020
Volume
126
Issue
7
Pages
1413–1423
Identifiers
DOI: 10.1002/cncr.32679
PMID: 31886908
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To the authors' knowledge, the question of whether human papillomavirus (HPV) infection is associated with outcomes in patients with sinonasal squamous cell carcinoma (SNSCC) is not well studied at this time. In the current study, the authors investigated patterns of HPV testing and its association with survival in patients with SNSCC using the National Cancer Data Base. The authors selected all SNSCC cases diagnosed between 2010 and 2016. HPV testing practices, clinicodemographic factors, treatments, and survival were analyzed. Multivariable Cox regression and propensity score-matched survival analyses were performed. A total of 6458 SNSCC cases were identified. Of these, only 1523 cases (23.6%) were tested for HPV and included in the current study. The median patient age was 64 years and the majority had advanced stage tumors (overall AJCC stage III-IV, 721 patients; 62.1%). HPV-positive SNSCC comprised 31.5% (447 of 1418 cases) of the final study cohort. Among 15 hospitals that routinely tested nonoropharyngeal SCCs for HPV, the percentage of HPV-positive SNSCCs was smaller (24.6%; P = .04). Patients with HPV-positive SNSCC were younger (aged 60 years vs 65 years; P < .001), with tumors that were more likely to be high grade (55.3% vs 41.7%; P < .001), and attributed to the nasal cavity (62.2% vs 44.0%; P < .001). HPV-positive SNSCC was associated with significantly improved overall survival in multivariable regression analysis (hazard ratio, 0.45; 95% CI, 0.28-0.72 [P = .001]) and propensity score-matched (hazard ratio, 0.61; 95% CI, 0.38-0.96 [P = .03]) analyses controlling for clinicodemographic and treatment factors. Currently, only a minority of patients with SNSCC are tested for HPV. However, a sizable percentage of SNSCC cases may be HPV related; furthermore, HPV-positive SNSCC is associated with improved overall survival. Routine HPV testing may be warranted in patients with SNSCC. © 2019 American Cancer Society.

Report this publication

Statistics

Seen <100 times